Infections related to TNF-α inhibitors

Expert Review of Dermatology

Volumn 1, Issue 5, 2006, Pages 737-749

  Orenstein, Robert ^a  

^a Mayo Clinic   (United States)

Author keywords

adalimumab; etanercept; infections; infliximab; TNF inhibitors

Indexed keywords

EID: 34250374611     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.1.5.737     Document Type: Article

References (109)

1. Furst DE, Breedveld FC, Kalden JE et al. Updated consensus statement on biological agents, specifically tumor necrosis factor α blocking agents and interleukin-1 receptor antagonist, for the treatment of rheumatic diseases, 2005. Ann. Rheum. Dis. 64 (Suppl. IV), IV2 –IV14 (2005).
2. Smith CH, Anstey AV, Barker JNWM et al. British association of dermatology guidelines for use of biological interventions in psoriasis 2005. Br. J. Derm. 153, 486–497 (2005).
3. Leonardi CL, Powers JL, Matheson RT. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349, 2014–2022 (2003).
4. Baker DG. Infliximab monotherapy provides rapid and sustained benefit for plaque type psoriasis. J. Am. Acad. Dermatol. 48, 829–835 (2003).
5. Antoni C, Kruger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150–1157 (2005).
6. Kalb R, Gurske J. Infliximab for the treatment of psoriasis: clinical experience at State University of New York Buffalo. J. Am. Acad. Dermatol. 10, 1016 (2005).
7. Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139, 1627–1632 (2003).
8. Mease PJ, Goffe BS, Metz J, Van der Stoep A, Fink B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356, 385–390 (2000).
9. Papp KA, Tyrling S, Lahfa M et al. A global Phase 3 randomized controlled trial of etanercept in psoriasis: safety, efficacy and effect of dose reduction. Br. J. Derm. 152, 1304–1312 (2005).
10. Gottlieb AB, Leonardi CL, Goffe BS et al. Etanercept monotherapy in patients with psoriasis: a summary of safety based on an integrated multistudy database. J. Am. Acad. Dermatol. 54, S92 –S100 (2006).
11. Chaudhari U, Romano P, Mulcahy CD, Dooley CT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque type psoriasis: a randomized controlled trial. Lancet 357, 1842–1847 (2001).
12. Reich K, Nestle FO, Papp KA et al. Infliximab induction and maintenance therapy for moderate-severe psoriasis: a Phase 3 multicentre double-blind trial. Lancet 366, 1367–1374 (2005).
13. Papp KA. The long term efficacy and safety of new biological therapies for psoriasis. Arch. Dermatol. Res. 298, 7–15 (2006).
14. Dinarello C. Anticytokine therapeutics and infections. Vaccine 21, S24 –S34 (2003).
15. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect. Dis. 3, 148–155 (2003).
16. Lin PL, Pawar S, Zinovik A et al. TNF and chemokine expression in granulomas on non-human primates infected with M. tuberculosis. Presented at: Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA 30 September–3 October 2004 (Abstract).
17. Deepe GS, Gibbons RS. T cells require tumor necrosis factor-α to provide protective immunity in mice infected with Histoplasma capsulatum. J. Infect. Dis. 193, 322–330 (2006).
18. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 44, 714–720 (2005).
19. Zganiacz A, Santosuosso M, Wang J et al. TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J. Clin. Invest. 113, 401–413 (2004).
20. Netea MG, Radstake T, Joosten LA et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Association with decreased interferon γ production and Toll-like receptor 4 expression. Arthritis Rheum. 48, 1853–1857 (2003).
21. Westhovens R, Yocum D, Han J et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities. A large randomized, placebo-controlled trial (The START trial). Arthritis Rheum. 54, 1075–1086 (2006).
22. Wallis RS, Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk if etanercept and infliximab. Semin. Arthritis Rheum. 34 (Suppl. 1), 34–38 (2005).
23. Dinarello CA. Differences between anti-tumor necrosis factor α monoclonal antibodies and soluble TNF-receptor antagonists in host defense impairment. J. Rheum. Supp. 74, 40–47 (2005).
24. Fleischman R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res. Ther. 6 (Suppl. 2), S12 –S18 (2004).
25. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum. 46, 2287–2293 (2002).
26. Hyrich K, Symmons D, Watson K, Silman A and the BSRBR Control Centre. Baseline comorbidity levels in biologic and standard disease modifying anti-rheumatic drug treated patients with rheumatoid arthritis: results from a national patient register. Ann. Rheum. Dis. 65, 895–898 (2006).
27. Enbrel Package insert (2005).
28. Humira Package insert (2005).
29. Remicade Package insert (2005).
30. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 53, 780–782 (2004).
31. Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126, 19–31 (2004).
32. Ljung T, Karlen P, Schmidt D et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53, 849–853 (2004).
33. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin. Gastroenterol. Hepatol. 4, 621–630 (2006).
34. Bathon JM, Martin RW, Fleischman RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343, 1586–1593 (2000).
35. Klareskog L, van der Heijde D, de Jager JP et al. and the TEMPO Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet 363, 675–681 (2004).
36. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann. Rheum. Dis. 65, 753–759 (2006).
37. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285 (2006).
38. Bassetti S, Wasmer S, Hasler P et al. Staphylococcus aureus carriage in patients with rheumatoid arthritis under conventional and anti-tumour necrosis factor α treatment. J. Rheum. 32, 2125–2129 (2005).
39. Brook I. Secondary bacterial infections complicating skin lesions. J. Med. Microbiol. 51, 808–812 (2002).
40. Giles JT, Bartlett SJ, Gelber AC et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 55, 333–337 (2006).
41. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Associations with prednisone, disease modifying antirheumatic drugs and anti-tumor necrosis factor therapy. Arthritis Rheum. 54, 628–634 (2006).
42. Wallis RS, Broder M, Wong J, Beenhower D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 39, 1254–1255 (2004).
43. Wallis RS, Broder M, Wong J, Beenhower D. Granulomatous infections associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261–1265 (2004).
44. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. and BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum. 52, 1766–1772 (2005).
45. Dixon WG, Hyrich KL, Watson K, Symmons DPM, Silman AJ and the BSR Biologics Register. Serious infection rates in patients receiving biologic therapy in the United Kingdom: results from the BSR Biologics Register. EULAR (2005) (Abstract OP0094).
46. Tubach F, Salmon-Ceron D, Ravaud P, Mariette X and the RATIO Study Group. The RATIO Observatory: French Registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNF α therapy. Joint Bone Spine 72, 456–460 (2005).
47. Listing J, Stranfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52, 3403–3412 (2005).
48. Mease PJ, Gladman DD, Ritchlin CT et al. and the ADEPT study group. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52, 3279–3289 (2005).
49. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under TNF-α therapy. Rheumatology 42, 617–621 (2003).
50. Kirby AC, Raynes JG, Kaye PM. The role played by tumor necrosis factor during localized and systemic infection with Streptococcus pneumoniae. J. Infect. Dis. 191, 1538–1547 (2005).
51. Harbath S, Garbino J, Pittet D, Pugin J. Is anti-tumor necrosis factor therapy associated with increased mortality in patients with severe sepsis caused by pneumonia. J. Infect. Dis. 189, 1743 (2004).
52. Baeten D, Kruithof E, Van den Bosch F et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defense in the pathogenesis of the disease? Ann. Rheum. Dis. 62, 829–834 (2003).
53. Gluck T, Linde HJ, Scholmerich J, Muller-Ladner U, Fiehn C, Bohland P. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum. 46, 2255–2257 (2002).
54. Slifman NR, Gershon SL, Lee KH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α neutralizing agents. Arthritis Rheum. 48, 319–324 (2003).
55. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum. 11, 3013–3022 (2003).
56. Cornillie F, Shealy D, D’Haens G et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol. Ther. 15, 463–473 (2001).
57. Fu A, Bertouch JV, McNeil HP. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis Rheum. 50, 3049 (2004).
58. Claudepierre P, Deprez X, Goupille P et al. Club Rheumatismes et Inflammation, French Society of Rheumatology. Anti-TNF α therapy and safety monitoring: clinical tool guide. Joint Bone Spine 72 (Suppl. 1), S1 –S58 (2005).
59. Maini R, St Clair EW, Breedveld F et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized Phase 3 trial. ATTRACT Study Group. Lancet 354, 1932–1939 (1999).
60. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF. Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum. 52, 2968–2974 (2005).
61. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50, 372–379 (2004).
62. Tuberculosis associated with blocking agents against tumor necrosis factor-α – California, 2002–2003. MMWR 53, 683–686 (2004).
63. Ormerod LP and British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 60, 800–805 (2005).
64. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48, 2122–2127 (2003).
65. Perez JL, Kupper H, Spencer-Green GT. Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe. Presented at: Program and Abstracts of the Annual Congress of the European League Against Rheumatism. Vienna, Austria 8–11 June 2005 (Abstract OP0093).
66. Hernandez-Cruz B, Ponce-de-leon-Rosales S, Sifuentes-Osornio J, Ponce-de-leon-Garduno A, Diaz-Jouanen E. Tuberculous prophylaxis in patients with steroid treatment and systemic rheumatic disease. A case control study. Clin. Exp. Rheumatol. 17, 81–87 (1999).
67. Lalvani A, Richeldi L, Kunst H. Interferon γ assays for tuberculosis. Lancet Infect. Dis. 5, 322–323 (2005).
68. American Thoracic Society/Centers for Diseases Control/Infectious Diseases Society of America. Treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167, 603–662 (2003).
69. Vidal CG, Fernandez SR, Lacasa JM et al. Paradoxical response to antituberculous therapy in infliximab treated patients with disseminated tuberculosis. Clin. Infect. Dis. 40, 756–759 (2005).
70. Narita M, Ashkin D, Hollender E, Pitchenik A. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med. 158, 157–161 (1998).
71. Wood KL, Hage CA, Knox KS et al. Histoplasmosis after treatment with anti-TNF therapy. Am. J. Crit. Care Med. 167, 1279–1283 (2003).
72. Hage CA, Wheat LJ, Twigg HL, Knoxx K. Infliximab does not affect dendritic cells’ mediated lymphoproliferative response to Histoplasma capsulatum. Clin. Infect. Dis. 41, 1685–1687 (2006).
73. Smith JG, Williams DM, Graybill JR. Tumor necrosis factor-α plays a role in host defense against Histoplasma capsulatum. J. Infect. Dis. 162, 1349–1353 (1990).
74. Lee JH, Slifman NR, Gershon SK et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonist’s infliximab and etanercept. Arthritis Rheum. 46, 2565–2570 (2002).
75. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am. J. Med. 112, 78–79 (2002).
76. Wheat J, Sarosi G, McKinsey D et al. Practice guidelines for the management of patients with histoplasmosis. Clin. Infect. Dis. 30, 688–695 (2000).
77. Vail GM, Young RS, Wheat LJ, Filo RS, Cornetta K, Goldman M. Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl. Infect. Dis. 4, 148–151 (2002).
78. McKinsey DS, Wheat LJ, Cloud GA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled double blind study. Clin. Infect. Dis. 28, 1049–1056 (1999).
79. Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. Arthritis Rheum. 50, 1959–1966 (2004).
80. Blair JE, Douglas DD, Mulligan DC. Early results of targeted prophylaxis for coccidioidomycosis in patients undergoing orthotopic liver transplantation within an endemic area. Transpl. Infect. Dis. 5, 3–8 (2003).
81. Dewsnup DH, Galgiani JN, Graybill JR et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. 124, 305–310 (1996).
82. Thomas CF, Limper AH. Pneumocystis pneumonia. N. Engl. J. Med. 350, 2487–2498 (2004).
83. Ding K, Shibui A, Yang Y, Takamoto M, Matsuguchi T, Sugame K. Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine pneumocystis pneumonia. Microbes Infect. 7, 195–203 (2005).
84. Tai TL, O’Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology 41, 951–952 (2002).
85. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor α therapy with infliximab for Crohn’s disease. Inflamm. Bowel Dis. 10, 657–660 (2004).
86. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor α antagonists. Medicine 84, 291–302 (2005).
87. Warris A, Bjorneklett, Gaustad P. Invasive aspergillosis associated with infliximab therapy. N. Engl. J. Med. 14, 1099 (2001).
88. DeRosa FG, Shaz D, Campagna AC, Dellaripa PF, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor α neutralizing antibody: a possible healthcare associated case? Infect Control Hosp. Epidemiol. 24, 7 (2003).
89. Coyle CM, Weis LM, Rhodes LV et al. Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen. N. Engl. J. Med. 351, 42–47 (2004).
90. Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor α antagonists. Clin. Infect. Dis. 37, 838–840 (2003).
91. Uhl EW, Moldawer LL, Busse WW, Jack TJ, Castleman WL. Increased TNF-α gene expression in parainfluenza type 1 (Sendai) virus-induced bronchiolar fibrosis. Am. J. Pathol. 152, 513–522 (1998).
92. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy. Ann. Intern. Med. 136, 174 (2002).
93. Estrach C, Abernethy VE, Dawson JK. Infections and anti-TNF therapy: strategies for screening based on clinical experience. Rheumatology 43, 115–116 (2004).
94. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn’s disease following anti-tumour necrosis factor therapy. Eur. J. Gastroenterol. Hepatol. 14, 1393–1395 (2002).
95. Haerter G, Manfras BJ, de Jong-Hesse Y, et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor α antibody therapy for rheumatoid arthritis Clin. Infect. Dis. 39, e88 –e94 (2004).
96. Cottone M, Pietrosi G, Martorana G et al. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn’s colitis. Am. J. Gastroenterol. 96, 773–775 (2002).
97. Swindell K, Goldfarb J, Danziger-Isakov L, Sabella C. Herpes zoster after infliximab for Crohn’s disease in adolescent patients. Presented at: 42nd Annual Meeting of the Infectious Diseases Society of America. Boston, MA, USA 30 September–3 October 2004 (Abstract 999).
98. Wolfe F, Michaud K. Rates and risk factors for herpes zoster in patients with rheumatoid arthritis. EULAR (2004) (Abstract OP0149).
99. Balandraud N, Roudier J, Roudier C. What are the links between Epstein–Barr virus, lymphoma, and tumor necrosis antagonism in rheumatoid arthritis? Semin Arthritis Rheum. 34 (Suppl. 1), 31–33 (2005).
100. Esteve M, Saro C, Gonzales-Huix F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53 (9), 1363–1365 (2004).
101. Ostuni P, Botsios C, Punzi L et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann. Rheum. Dis. 62, 686–687 (2003).
102. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann. Rheum. Dis. 63 (Suppl. II), II18 –II24 (2004).
103. Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology and microbiology of adjunctive etanercept in HIV-1 associated tuberculosis. AIDS 18, 257–264 (2004).
104. Cursiefen C, Grunke M, Dechant C, Antoni C, Junemann A, Holbach LM. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF α-antibody and methotrexate therapy. Am. J. Ophthalmol. 134, 270–271 (2002).
105. Mariette X, Salmon D. French Guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann. Rheum. Dis. 62, 791 (2003).
106. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatments. Rheumatology 44, 1205–1206 (2005).
107. Orenstein R. Travel in patients receiving TNF-α inhibitors. Travel Med. Infect. Dis. 3, 105–109 (2005).
108. Elkyam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Seminars Arthritis Rheum. 33, 283–288 (2004).
109. Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis patients: the effect of disease modifying drugs, including TNF α blockers. Arthritis Rheum. 65, 191–194 (2006).